Wealthsource Partners LLC continued to hold its position in GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,205 shares of the pharmaceutical company’s stock at the close of the second quarter. Wealthsource Partners LLC’s holdings in GlaxoSmithKline PLC were worth $224,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its position in shares of GlaxoSmithKline PLC by 1,747.4% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 2,359 shares in the last quarter. Proficio Capital Partners LLC grew its position in shares of GlaxoSmithKline PLC by 233.0% during the 1st quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after buying an additional 1,990 shares in the last quarter. Westwood Holdings Group Inc. grew its position in shares of GlaxoSmithKline PLC by 15.7% during the 1st quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after buying an additional 400 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its position in shares of GlaxoSmithKline PLC by 1.9% during the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after buying an additional 64 shares in the last quarter. Finally, FTB Advisors Inc. grew its position in shares of GlaxoSmithKline PLC by 16.9% during the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock worth $146,000 after buying an additional 539 shares in the last quarter. 9.28% of the stock is currently owned by institutional investors and hedge funds.

GlaxoSmithKline PLC (NYSE GSK) traded down 0.02% during midday trading on Friday, reaching $41.01. The company’s stock had a trading volume of 4,354,724 shares. The firm has a market capitalization of $100.23 billion, a PE ratio of 39.74 and a beta of 1.03. The stock’s 50-day moving average price is $40.35 and its 200 day moving average price is $41.58. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion during the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. Equities analysts anticipate that GlaxoSmithKline PLC will post $2.87 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 12th. Stockholders of record on Friday, August 11th were given a dividend of $0.491 per share. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a dividend yield of 4.79%. The ex-dividend date of this dividend was Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio is currently 198.00%.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/10/15/wealthsource-partners-llc-has-224000-stake-in-glaxosmithkline-plc-gsk.html.

GSK has been the topic of a number of recent research reports. Zacks Investment Research raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a research report on Tuesday, July 18th. Argus restated a “buy” rating and set a $50.00 price objective on shares of GlaxoSmithKline PLC in a research note on Thursday, August 31st. TheStreet cut GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, September 21st. Finally, Citigroup Inc. cut GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 5th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $44.67.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.